Background: While an elevated risk of second malignant neoplasms (SMNs) has been observed in men treated for germ cell tumors (GCTs), risk of SMNs have not been quantified in adult women or in girls treated for GCTs.
Introduction
Since the 1980s, cisplatin-based chemotherapy has been the primary treatment of germ cell tumors (GCTs). The regimen and dosing used are similar for both males and females treated for GCT. Many studies have now documented that men treated for primary GCT experienced 1.4-to 1.9-fold elevation in the risk of developing second malignant neoplasms (SMNs) [1, 2] . Sites with significantly elevated risk of SMN development include the pancreas, soft tissue, bladder, kidney, and thyroid [2] . Whether the risk of SMN identified in men is applicable to women and girls is unclear. In this study, we explore rates of SMNs in females treated for GCT and discuss what insights these findings may provide in terms of susceptibility to SMNs.
Patients and methods
This study included 1507 1-year female survivors of GCTs diagnosed between January 1, 1980 , and December 31, 2012, from Surveillance, Epidemiology, and End Results (SEER 9) registries. Cases with malignant behavior were identified using International Classification of Diseases (ICD)-O-3 morphology codes 9060, 9064-9065, 9070-9072, 9080-9083, 9085, 9090, and 9100-9101. Childhood cases were defined as girls diagnosed with primary GCT from birth to the age of 19 years, whereas adult cases include women diagnosed at the age of 20 years or later. Follow-up period began 1-year after the primary GCT diagnosis and continued until death or study end date (December 31, 2013), whichever came first. Patients whose primary GCT tumors occurred in the central nervous system (N ¼ 24) or was a choriocarcinoma of the placenta (N ¼ 347) were not included in this analysis. Third-or higher-ordered cancers (N ¼ 2 cancers in two patients) were included in the analysis.
Risks of SMNs (excluding ovarian cancers) with 95% confidence intervals (CIs) were estimated using multiple primary -standardized incidence ratio (SIR) sessions in SEER*Stat, following previously reported methods [3, 4] . Statistical significance was defined as P 0.05 (two sided).
Results
A total of 47 SMNs were identified in 45 patients: 36 were found in females treated for GCT as adults and 11 were in females treated for GCT as girls (Table 1) . Third-ordered cancers were only observed in females diagnosed with GCT as adults (N ¼ 2). The risk of SMNs was not elevated in all females (SIR ¼ 1.11, 95% CI 0.81-1.47) or in women treated for GCT as adults alone (SIR ¼ 0.98, 95% CI 0.7-1.33). The number of SMNs in childhood cases of GCT was too few to be studied as a group. Therefore, these cases were combined with SMNs observed in women treated for GCT as adults in all subsequent analysis.
Similar to other studies, malignant teratoma was the most common histology of primary GCTs in this cohort [5, 6] . However, the SEER database is limited by the classification of malignant teratoma in ICD-O-3. It is unclear whether malignant immature teratoma with a second germ cell element was grouped with teratoma, the other germ cell element, or as mixed GCT. While all patients with stage I, grade 1 mature teratoma received surgery only, there is a controversy as to how patients with higher grade and stage immature teratoma should be treated. Although all adult patients with immature teratoma (except those with stage I, grade 1 disease) received postoperative chemotherapy, only some pediatric patients did so at the discretion of their physician [7] . Nevertheless, when malignant teratoma was excluded from the analysis, the overall conclusions of this study were unaffected (all females: SIR ¼ 1.32, 95% CI 0.92-1.84), women treated for adulthood GCT: SIR ¼ 1.13, 95% CI 0.74-1.66).
Nonsignificant elevated risk of SMN was observed in the pancreas (SIR ¼ 3.42, 95% CI 0.41-12.35), soft tissue (SIR ¼ 5.16, 95% CI 0.62-18.64), bladder (SIR ¼ 1.74, 95% CI 0.04-9.71), kidney (SIR ¼ 2.11, 95% CI 0.26-7.63), and thyroid (SIR ¼ 1.61, 95% CI 0.59% to 3.50%) ( Table 2) . A significant elevated risk of CNS cancer was found (SIR ¼ 5.43, 95% CI 1.48-13.90), with three cases in women diagnosed with GCT at <10 years of age and one in a woman diagnosed with GCT as an adult.
When the risk of developing site-specific SMNs was stratified by latency, significantly elevated risk of CNS (SIR ¼ 9.82, 95% CI 2.03-28.7) and thyroid (SIR ¼ 3.88, 95% CI 1.26-9.04) tumors were observed in the first decade after GCT diagnosis, whereas pancreatic cancer (SIR ¼ 8.39, 95% CI 1.02-30.32), soft tissue cancer (SIR ¼ 21.05, 95% CI 2.55-76.06), and mesothelioma (SIR ¼ 97.03, 95% CI 2.46-540.59) were observed in the second decade or later in follow-up. Information on treatment in SEER is limited: some information is available on radiotherapy but not on chemotherapy. Since chemotherapy is the primary treatment for GCT, our ability to evaluate the impact of treatment on risk of SMN is limited. Less than 6% of females received radiotherapy, therefore we did not have enough power to conduct stratified analyses (data not shown).
Discussion
Unlike in men, risk of SMNs overall is not significantly elevated in females treated for GCT although the small sample size limited our ability to detect modest increases in risk. We did observe elevated risk estimates at sites where SMN commonly occur in men, although without statistical significance for most tumor sites. The elevated risk of CNS tumors observed is unexpected as second brain tumors are rare as second solid tumors in men with GCT [3] . When stratified by latency, the elevated risk observed in site-specific SMNs is similar to that previously reported in men, which suggest a common second cancer progenitor in those sites between the sexes [1] .
In comparison to males, GCTs in females are rare, as the incidence of GCTs in males overall is 15-25 times higher than in females with the exception of the 0-to 4-years age group [8] [9] [10] . Nonetheless, the large number of patients in our study should provide sufficient power to detect an increase of SMNs in females, had there been an association of comparable magnitude as that in men. From the 95% CI calculated for the risk of SMNs, our analysis does not exclude the possibility of elevated risk of SMNs. However, an SIR of 1.11 is not highly suggestive of an elevated risk. In many rare tumors, it is difficult to determine an accurate relative risk of second malignancy as databases for these tumors are often inadequate.
While we did not observe a significant elevated risk of SMNs overall among females treated for GCTs, similar trends and sites of SMNs suggest that studies with larger sample size and longer follow-up are warranted.
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